Objective: The Surviving Sepsis Campaign guidelines recommend obtaining a serum lactate measurement within 6 hours of presentation for all patients with suspected severe sepsis or septic shock. A lactate greater than 4 mmol/L qualifies for administration of early quantitative resuscitation therapy. We evaluated lactate elevation (with special attention to values > 4 mmol/L) and presence or absence of hypotension as a marker of clinical outcome. Design and Setting: The Surviving Sepsis Campaign developed a database to assess the overall effect of the sepsis bundles as a performance improvement tool for clinical practice and patient outcome. This analysis focuses on one element of the Surviving Sepsis Campaign's resuscitation bundle, measuring serum lactate in adult severe sepsis or septic shock patients and its interaction with hypotension. This analysis was conducted on data submitted from January 2005 through March 2010. Subjects: Data from 28,150 subjects at 218 sites were analyzed. Interventions: None. Measurements and Main Results: Unadjusted analysis of the 28,150 observations from the Surviving Sepsis Campaign database demonstrated a significant mortality increase with the presence of hypotension in conjunction with serum lactate elevation greater than 2 mmol/L. On multivariable analysis, only lactate values greater than 4 mmol/L, in conjunction with hypotension, significantly increased mortality when compared with the referent group of lactate values less than 2 mmol/L and not hypotensive. Mortality was 44.5% in patients with combined lactate greater than 4 mmol/L and hypotension when compared with 29% mortality in patients not meeting either criteria. Conclusions: Serum lactate was commonly measured within 6 hours of presentation in the management of severe sepsis or septic shock in this subset analysis of the Surviving Sepsis Campaign database in accordance with the Surviving Sepsis Campaign guidelines. Our results demonstrate that elevated lactate levels are highly associated with in-hospital mortality. However, only patients who presented with lactate values greater than 4 mmol/L, with and without hypotension, are significantly associated with in-hospital mortality and is associated with a significantly higher risk than intermediate levels (2-3 and 3-4 mmol/L). This supports the use of the cutoff of greater than 4 mmol/L as a qualifier for future clinical trials in severe sepsis or septic shock in patient populations who use quantitative resuscitation and the Surviving Sepsis Campaign bundles as standard of care. (Crit Care Med 2015; 43:567-573) Key Words: Surviving Sepsis Campaign; sepsis mortality; serum lactate A significant amount of evidence accumulated in the literature demonstrates that lactate is a useful predictor of outcome in severe sepsis and septic shock (1-3).
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Since December 2010 the SSC has been funded with an unrestricted grant from the Gordon and Betty Moore Foundation. However, unresolved controversies remain regarding the true role of lactate in severe sepsis (4) (5) (6) . With the publication of the Surviving Sepsis Campaign (SSC) analysis of 15,000 patients and the intention to revise the SSC bundles with the publication of the 2012 SSC Guidelines, we felt it was important to use the large approximately 30,000 patient SSC database to confirm the relationship between lactate and mortality to justify continue use of lactate measurement as a bundle element for risk assessment (7) .
Unanswered questions regarding lactate in sepsis do remain. As the care of septic patients improve, will lactate remain a good marker of risk? As new trials involving early resuscitation have been published, and the components of "usual" care for patients with severe sepsis and septic shock evolve, we believe that it is important to re-evaluate the value of serum lactate measurement in the routine management of these patients (8) . More specifically, is a lactate level greater than 4 mmol/L still accurate for identifying patients as significant mortality risk?
The Surviving Sepsis Campaign database is the largest prospectively collected database in severe sepsis and septic shock patients that also records clinical practice patterns over time (9) and has been used to improve outcomes (7) . Therefore, we sought to evaluate the relationship between lactate and mortality in severe sepsis and septic shock and the choice of lactate greater than 4 mmol/L as the marker of greater risk and initiation of protocol-guided resuscitation in patients with severe sepsis and septic shock. We also wanted to evaluate the relationship between patient mortality and routine measurement of lactate as part of the sepsis bundles and to re-assess the validity of and lactate level, as well as a lactate level greater than 4 mmol/L, to identify patients at higher risk of death.
METHODS

Sites and Patient Selection
The process of participation in the SSC is described in detail elsewhere (7) . Eligible subjects were those having a suspected site of infection, two or more systemic inflammatory response syndrome criteria, and one or more organ dysfunction criteria (10, 11) . Clinical characteristics and the time of meeting severe sepsis and septic shock criteria were collected for analysis of time-based performance measures. Time of meeting severe sepsis and septic shock criteria was determined by the origin at time of presentation. In patients presenting from the emergency department (ED), time zero is ED triage time. For patients presenting with severe sepsis or septic shock in areas other than the ED, time zero is determined when the patient met screening tool criteria for severe sepsis or septic shock or time of beginning of resuscitation and severe sepsis and septic shock management from clinical annotation in the chart. Data collection instructions were provided to site data collectors through the SSC website, printed material, and in-person educational sessions.
Data Collection
Data were entered into the SSC database at participating hospitals into pre-established, unmodifiable fields documenting performance data and the time of specific actions and findings. Data stripped of private health information were submitted to the secure master SSC server at the Society of Critical Care Medicine (Mount Prospect, IL) via file transfer protocol or as comma-delimited text files attached to e-mail submitted to the Campaign's server.
Institutional Review Board Approval
Analysis of the data for the global SSC improvement initiative was approved by the Cooper University Hospital Institutional Review Board (Camden, NJ) as meeting criteria for exempt status. The US Department of Health and Human Services' Office for Human Research Protections reiterated that quality improvement activities such as SSC often qualify for institutional review board exemption and do not require individual informed consent (12).
Analysis Set Construction
The analysis set was constructed from the subjects entered into the SSC database from January 2005 to March 2010. Inclusion was limited to sites with at least 20 subjects and at least 3 months of data. Data were organized by quarter through 4 years of participation in the Campaign. The first 3 months that a site entered subjects into the database was defined as the first quarter regardless of when those months occurred from January 2005 to March 2010. All relevant patient characteristics recorded in the database were eligible for inclusion in the riskadjustment models.
Statistical Analysis
The primary goal of the study was to evaluate lactate elevation (with special attention to values > 4 mmol/L) within 6 hours after identification of severe sepsis and septic shock and the presence or absence of hypotension as a marker of clinical outcome. Therefore, lactate was dichotomized at greater than 4 mmol/L (yes vs no). Furthermore, the presence of hypotension was a strong effect modifier of dichotomized lactate's association with in-hospital mortality. Hypotension is defined based on the patient's having any of the following: systolic blood pressure less than 90 mm Hg, or mean arterial pressure less than 65 mm Hg, or a decrease of 40 or more mm Hg from known baseline. Consequently, a single categorical risk factor with four levels was created using these two dichotomized variables and is nominally called lactate/hypotension. We compared clinical characteristics of patients across four groups of lactate/hypotension where categorical variables are presented as frequencies and percentages, whereas continuous variables are presented as medians and the interquartile range. Differences across groups were determined using Pearson chi-square test of association for categorical variables and Wilcoxon rank-sum for continuous variables. Several logistic regression models were developed to assess the association between mortality and lactate/hypotension. We used a risk factor modeling approach to determine which covariates to add to the logistic regression model. Only covariates that acted either as a confounder or as an effect modifier were included. A confounder was identified when its addition to the model changed any of the odds ratios associated with lactate/hypotension by more than 10% in either direction, without considering statistical significance. A covariate that had any statistically significant interaction (p ≤ 0.05) with lactate/hypotension was considered to be an effect modifier. Specifically, a generalized estimating equation (GEE) logistic regression was used because patients are nested within a particular ICU. This method takes into account the variability within and between ICUs and uses this inherent correlation when estimating the ses that are used to test model coefficients. The hierarchical nature of the SSC data lends itself to this type of analysis. A sensitivity analysis used multiple imputation (n = 20) where missing lactate values (n = 4,419;15.7%) were regressed on 30 covariates using truncated linear regression. The four-level risk factor was recreated, and the GEE logistic regression model was re-run. All analyses were run using Stata 12.1 (Stata Corporation, College Station, TX).
RESULTS
Subjects
Between January 2005 and March 2010, the SSC database consisted of 28,150 patients at 218 hospitals (median equal to 57 and a range of 20-471 subjects per hospital). Each site contributed to the database between 1 and 21 quarters of data for a mean duration of 21 months (median, 20 months). A consort diagram ( Fig. 1) illustrates that 4,419 (15.7%) subjects were missing serum lactate measurements. The subjects were assumed to be missing completely at random because we failed to detect a difference in the in-hospital mortality between those with a serum lactate and those without. Mortality was 33.3% and 34.6%, respectively (p = 0.104). In addition, to determine whether a relationship exists between missing lactate and hypotension, we tested whether the odds of hypotension changed over time for those missing and those without missing serum lactate values and found that the odds did not change with each site quarter increase (p = 0.076 and 0.422, respectively). Removal of 4,419 subjects with missing lactate left 23,731 subjects for the analysis of continuous serum lactate by hypotension status and whether or not it was measured within 6 hours per SSC resuscitation bundle guidelines. For the primary analysis, we used only those lactate values that were measured within 6 hours, thus we removed 3,786 observations leaving 19,945 subjects for the primary analysis.
Patient Characteristics and Effect on Mortality
The clinical characteristics of the 19,945 patients in the four different lactates groups who presented with presence or absence of lactate greater than 4 mmol/L in less than or equal to 6 hours with or without hypotension are detailed and compared in Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/B134). Patients who presented with lactate greater than 4 mmol/L with hypotension showed a significantly higher mortality of 44.5% compared with the other three groups, who had a mortality of approximately 29%. Hospital mortality differs across location where severe sepsis and septic shock were identified; however, in the adjusted regression analyses, there were no statistically significant interactions between the four groups and location. Thus, location was entered into the regression model as a confounder and not as an effect modifier. No significant differences with respect to hospital length of stay, the location of severe sepsis or septic shock identification, or number of organ dysfunctions appear among the groups.
The common sites of infection include pneumonia, urinary tract, and abdomen, which comprised more than 80% of cases and with no significant differences among the lactate groups. When reviewed by region (Europe, United States, and South America), the patient characteristics were found to be consistent with the results above on the entire analysis population (data not shown). Similarly, data reviewed by the location of severe sepsis and septic shock identification (ED, ward, or ICU) found results consistent with the entire population (data not shown).
Unadjusted Lactates Associated With In-Hospital Mortality
Statistical analysis on all 23,731 observations without missing lactate values from the SSC database showed a statistically significant increase in the odds of in-hospital mortality in patients presenting with lactate values greater than 4 mmol/L compared with those with lactate values less than or equal to 2, greater than 2 to less than or equal to 3, and greater than 3 to less than or equal to 4 mmol/L independent of hypotension status or when lactate was measured. This analysis was determined using an unadjusted GEE population-averaged logistic regression model ( Table 1) . Even at lactate concentrations of 2-3 and 3-4 mmol/L, a significant increase appears in the odds of mortality in the hypotensive patients compared with lactate less than 2 mmol/L. This association is consistent regardless of whether lactate is measured less than or equal to 6 or greater than 6 hours. Figure 2 illustrates the linear increase in predicted in-hospital mortality with increasing serum lactate measured on a continuous basis using a similar GEE model. Whether the lactate was drawn in patients with severe sepsis or septic shock less than or equal to 6 or greater than 6 hours or in the presence or absence of hypotension, all four of these groups had a statistically significant in-hospital mortality odds ratio for a 1-unit increase in serum lactate. The association between an elevated lactate and in-hospital mortality is strongest (odds ratio, 1.26; 95% CI, 1.21-1.32; p < 0.001) in those hypotensive patients whose lactate was measured greater than 6 hours, whereas the association is weakest (odds ratio, 1.07; 95% CI, 1.03-1.11; p = 0.001) in non-hypotensive patients measured less than or equal to 6 hours. Table 2 shows the adjusted and unadjusted odds ratios from a GEE logistic regression analysis of the 19,945 patients whose lactate was measured within 6 hours of severe sepsis and septic shock identification. The odds ratios for the three groups (lactate > 4 mmol/L and not hypotensive; lactate ≤ 4 mmol/L and hypotensive; and lactate > 4 mmol/L and hypotensive) compared with lactate ≤ 4 mmol/L and not hypotensive are adjusted for the following confounding variables: fluids and vasopressor compliance; central venous pressure ≥ 8 mm Hg compliance; Scvo 2 ≥ 70% compliance; inspiratory plateau pressure less than 30 cm H 2 O compliance; severe sepsis and septic shock admission source (ED, ward, or ICU); geographic region (United States, Europe, or South America); mechanical ventilation; pulmonary organ failure; the interaction between mechanical ventilation and pulmonary organ failure; and number of baseline organ failures. The cutoff of greater than 4 mmol/L with hypotension was the only level that was still significantly different from the referent group (≤ 4 mmol/L and not hypotensive) after adjustment using our multivariable analysis. When this analysis was repeated for specific subpopulations (Europe, United States, or South America) and point of severe sepsis and septic shock identification in the hospital (ICU, ED, or ward), the results were consistent with the entire sample (results not shown). A sensitivity analysis used multiple imputation (n = 20) to impute the 4,419 missing lactate values. The adjusted odds ratios again indicated that only lactate greater than 4 mmol/L and hypotensive were significantly different from less than or equal to 4 mmol/L and not hypotensive. The in-hospital mortality odds ratios were 1.17 (95% CI, 0.94-1.45; p = 0.153), 0.97 (95% CI, 0.83-1.14; p = 0.721), and 1.64 (95% CI, 1.39-1.94; p < 0.001) for lactate greater than 4 mmol/L and not hypotensive, lactate less than or equal to 4 mmol/L and hypotensive, and lactate greater than 4 mmol/L and hypotensive, respectively. In patients with high lactate levels (> 4 mmol/L) who were not hypotensive, i.e., patients with the so-called cryptic septic shock, the adjusted odds ratios were not statistically significant. 
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Figure 2.
In-hospital mortality compared to serum lactate when measured continuously.
declined in the hospital sites participating for at least 2 years. The unadjusted odds ratio for overall lactate compliance is 1.06 (95% CI, 1.05-1.07; p < 0.001), indicating lactate compliance increases 6% per site quarter.
DISCUSSION
Seminal work by Broder and Weil (13) studied 56 patients in shock from a variety of causes and found a mortality rate of 89% when a single lactate value was greater than or equal to 4 mmol/L. Aduen et al (14) investigated lactate levels in a cross section of 180 undifferentiated ICU patients. They found that lactate levels were significantly higher in nonsurvivors, regardless of blood pressure. Other authors have focused on patients specifically with septic shock (15). Bakker et al (16) focused on 48 ICU patients with septic shock and found that initial and serial blood lactate levels were superior to pulmonary arterial catheter-derived data in predicting mortality. Vincent et al, Bakker et al, and Falk et al (16) (17) (18) found that serial lactate levels predicted mortality in ICU patients with septic shock, but that initial levels had less of a prognostic ability. The present study uses a large, prospectively collected and recorded database of lactate values and clinical outcomes to confirm previous investigations about the prognostic use of lactate levels. The SCC database includes a large population of patients who were admitted to the hospital with severe sepsis and septic shock and used the SSC guidelines as standard of care. On the basis of analysis of 19,945 subjects from the SSC database, our study is the largest comparative analysis of the association between lactate and in-hospital mortality in patients presenting with severe sepsis or septic shock. The application of the SSC bundles has already been demonstrated to improve outcomes in patients with severe sepsis and septic shock as a result we wanted to evaluate the prognostic value of lactate in those circumstances. Our results demonstrate that lactate remains an effective risk-stratification biomarker in patients where the SCC guidelines are applied as standard of care. This analysis was repeated for each individual geographic location, i.e., Europe, United States, and South America, and each individual location in the hospital where the severe sepsis or septic shock was initially identified, i.e., ED, ICU, or ward, without any changes in results. Regardless of where the data were obtained, our results were consistent in highlighting the association between rising lactate levels and in-hospital mortality.
An unadjusted logistic regression model demonstrated that when combining the presence of hypotension and the timing of the lactate measurement, the association between an elevated lactate and in-hospital mortality is strongest (highest odds ratio) in those hypotensive patients whose lactate was measured greater than 6 hours, whereas the association is weakest in nonhypotensive patients measured less than or equal to 6 hours (Table 1 ). In addition, intermediate lactate levels were associated with increased risk of mortality (Fig. 2) . However, the adjusted analysis also demonstrated that the lactate cutoff of greater than 4 was the only cutoff to have a statistically significant association with in-hospital mortality in all four patient groups, namely lactate drawn within 6 or after 6 hours and/or in the presence or absence of hypotension ( Table 1 ). The unadjusted analysis justified the use of the cutoff value of lactate greater than 4 mmol/L in the subsequent multivariable analysis (Table 2 ).
Our results demonstrate that only patients who presented with lactate values greater than 4 mmol/L in the presence of hypotension were associated with in-hospital mortality after adjusting for the confounding variables. Only patients meeting both criteria (elevated lactate and hypotension) show a statistically significant association after risk adjustment (Table 2) . Similarly, Howell et al (2) demonstrated an adjusted odds ratio of 7.1 for patients with increased blood lactate of greater than 4 mmol/L (after adjustment for age and blood pressure). Furthermore, the study by Rivers et al (19) showed the importance of blood lactate concentrations greater than or equal to 4 mmol/L in the context of early goal directed therapy. Our data support that a lactate value greater than 4 mmol/L is an appropriate cutoff for future clinical trials designed to improve outcome in severe sepsis and septic shock where quantitative resuscitation is being applied as standard in adherence with SSC guidelines. Although we found the commonly used cutoff value of greater than 4 mmol/L for lactate with hypotension to be the only cutoff statistically associated with in-hospital mortality following multivariable analysis, our results confirm that all lactate values greater than or equal to 2 mmol/L have a clinical value because their association with increased mortality is shown to increase linearly (Fig. 2) . Our results are in keeping with other studies that examined ED patient populations suggest that patients with intermediate lactate values between 2 and 4 may also benefit from quantitative resuscitation (20, 21) . However, this preliminary data will need to be verified in prospective clinical trials. Despite their inherent weaknesses, categorical variables are often the only practical solution when creating inclusion criteria for clinical trials and their cutoff values are important in assessing therapeutic intervention or quality improvement projects (22) .
Our article also looked at a population of patients with cryptic septic shock. This is a particularly important group of patients because compensated shock is not easily recognizable (23, 24) . Delayed identification of hypoperfusion may lead to inadequate or delayed resuscitation, which is strongly associated with increased mortality (25, 26) . Our data suggest that serum lactate levels are associated with mortality in septic shock, even in the absence of hypotension ( Fig. 2 and Table 1 ). Therefore, lactate levels may be helpful in deciding which patients could benefit from aggressive treatment strategies because lactate is shown to be independently associated with mortality (25, 26) . However, lactate appears to be more highly associated with hospital mortality when combined with hypotension. Hernandez et al (27) highlighted the need to interpret hypotension in the context of lactate levels when they demonstrated that hypotension in septic patients does not portend a poor outcome if that lactate levels remain within normal range. Ultimately, a cutoff of 4 mmol/L was not significant in the absence of hypotension after an adjusted multivariable analysis, which suggests that more stringent criteria may be required in clinical trials of severe sepsis and septic shock that include this subgroup of patients. It may also represent an improvement in patient outcome in the patients who have demonstrated a blood pressure response to quantitative resuscitation. However, this result may be, in part, because of the small fraction of the total patient population in our database (n = 996).
In this large population, there was an association with increased lactate values at presentation and an increase in inhospital mortality in patients presenting with severe sepsis or septic shock. Interestingly, this association persisted whether the lactate was measured less than or equal to 6 and greater than 6 hours from presentation. The lactate measurement of greater than 4 mmol/L after 6 hours may be a powerful indicator of in-hospital mortality because it reflects failure to clear lactate effectively in response to resuscitation efforts. However, it may also reflect a delay in initiating resuscitation efforts, which could also contribute to high mortality in severe sepsis and septic shock (28) . Unfortunately, our database does not allow us to make that distinction.
Lactate has been used not only as a marker of risk but also to guide therapy (21) . A study by Jansen et al (29) showed that a treatment protocol aimed at reducing lactate levels by 20% in 2 hours resulted in a significant reduction in in-hospital mortality. In this study, although lactate served as a warning signal for more aggressive therapy that resulted in decreased mortality, more aggressive therapy did not succeed in faster lactate clearance compared with the control group (29) . Therefore, the therapeutic intervention succeeded in improving outcomes without an improvement in lactate clearance. This suggests dissociation between lactate measurement and in-hospital mortality, undermining its ability to predict in-hospital mortality. Contrary to the finding of Jansen et al (29) where failure to clear lactate did not separate patients who did or did not respond to quantitative resuscitation, our results present evidence of preservation of the association between increased lactate and increased inhospital mortality in a patient population who received quantitative resuscitation according to the SSC guidelines (Table 1 and Fig. 2 ). This suggests that further studies are needed to confirm the mortality benefit from reducing blood lactate levels through the proposed resuscitation strategy that uses serial lactate measurements to guide therapeutic endpoints resuscitation for two reasons: First, to validate the findings of Jansen et al (29) and to identify how patient outcome improved in the absence of an effect on serial lactate levels.
We also examined the measurement of serum lactate in severe sepsis and septic shock in the SSC database over time. Our results show that the measurement of lactate in severe sepsis and septic shock increased over time. This reflects the success of the sepsis bundles as part of a performance improvement initiative in improving physician compliance with a known quality indicator in the management of severe sepsis (30) .
Our study is clearly limited by its observational design. However, observational studies can provide valuable information on treatment effectiveness (31) . Moreover, observational studies maximize external validity and often reflect real-life practice more accurately than randomized controlled trials (32) . The SSC database was designed to provide a description of the management and outcomes of severe sepsis and septic shock patients, reflecting everyday clinical practice within the boundaries of the SSC guidelines (33) . Data resulting from secondary analysis of the SSC database will serve as an ongoing audit for the effectiveness of the individual components of the care bundles devised by the SSC (34).
In conclusion, patients admitted to the hospital who present with a clinically suspected significant infection and a single measurement of venous lactate value greater than 4 mmol/L in the presence of hypotension have been shown to be associated with in-hospital mortality in patients receiving the SSC care bundles. This supports the continued use of greater than 4 mmol/L as the trigger for quantitative resuscitation in the SSC guidelines and bundles although the increasing mortality associated with intermediate lactate levels (2-4 mmol/L) would suggest that this patient population would also derive benefit from quantitative resuscitation and highlights the need for those clinical trials to be performed.
